MiNK Therapeutics, Inc. (INKT)

NASDAQ: INKT · IEX Real-Time Price · USD
1.010
-0.030 (-2.88%)
At close: May 17, 2024, 4:00 PM
1.060
+0.050 (4.95%)
After-hours: May 17, 2024, 7:21 PM EDT
-2.88%
Market Cap 35.60M
Revenue (ttm) n/a
Net Income (ttm) -20.59M
Shares Out 34.73M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 64,417
Open 1.020
Previous Close 1.040
Day's Range 0.980 - 1.040
52-Week Range 0.750 - 3.340
Beta 0.03
Analysts Strong Buy
Price Target 9.00 (+791.09%)
Earnings Date May 14, 2024

About INKT

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 15, 2021
Employees 31
Stock Exchange NASDAQ
Ticker Symbol INKT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for INKT stock is "Strong Buy" and the 12-month stock price forecast is $9.0.

Price Target
$9.0
(791.09% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

MiNK Reports First Quarter 2024 Results

NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic...

4 days ago - GlobeNewsWire

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic...

5 days ago - GlobeNewsWire

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...

18 days ago - GlobeNewsWire

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...

5 weeks ago - GlobeNewsWire

MiNK Reports Fourth Quarter and Year-End 2023 Results

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) --  MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogen...

2 months ago - GlobeNewsWire

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...

2 months ago - GlobeNewsWire

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model MiNK-215 Eradicated Tumor Cells in Human Organoid MSS Colorectal Cancer Liver Metastases Model

2 months ago - GlobeNewsWire

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...

3 months ago - GlobeNewsWire

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

SAN DIEGO and NEW YORK and SINGAPORE, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ImmunoScape , a biotechnology company focused on the discovery and development of next-generation T cell receptor (TCR)-based th...

5 months ago - GlobeNewsWire

MiNK Therapeutics Reports Third Quarter 2023 Results

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...

6 months ago - GlobeNewsWire

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

NEW YORK, Nov. 03, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...

7 months ago - GlobeNewsWire

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogenei...

7 months ago - GlobeNewsWire

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...

8 months ago - GlobeNewsWire

MiNK Therapeutics to Participate in September Investor Conferences

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic,...

9 months ago - GlobeNewsWire

MiNK Therapeutics Reports Second Quarter 2023 Results

-  Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center

10 months ago - GlobeNewsWire

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic,...

10 months ago - GlobeNewsWire

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic...

1 year ago - GlobeNewsWire

MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference

NEW YORK, May 22, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic,...

1 year ago - GlobeNewsWire

MiNK's Novel FAP-CAR-iNKT Presented at ASGCT

NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic,...

1 year ago - GlobeNewsWire

MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic...

1 year ago - GlobeNewsWire

MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...

1 year ago - GlobeNewsWire

MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting

NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogenei...

1 year ago - GlobeNewsWire

MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

NEW YORK, March 21, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...

1 year ago - GlobeNewsWire

MiNK Therapeutics to Present Updated Clinical Data of allo-iNKT Cell Therapy in Solid Tumors at AACR Annual Meeting

– Clinical update of allo-iNKT cells (agenT-797) alone or in combination with approved anti-PD-1 in advanced solid tumors

1 year ago - GlobeNewsWire

MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogene...

1 year ago - GlobeNewsWire